Spero Therapeutics, Inc.
SPRO
Rank in Stocks
#21807
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical... Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments. SPR720, an oral antibiotic targeting non-tuberculous mycobacterial (NTM) pulmonary disease. Spero Therapeutics has also forged several strategic alliances: A licensing agreement with Meiji Seika Pharma Co., Ltd. supports the ongoing development of tebipenem HBr. A separate licensing deal with Everest Medicines grants rights for the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and various Southeast Asian nations. The company collaborates with the Bill & Melinda Gates Medical Research Institute to advance SPR720 for treating lung infections caused by Mycobacterium tuberculosis. Furthermore, a licensing agreement with Vertex Pharmaceuticals Incorporated covers patents associated with SPR720 and its active metabolite, SPR719. Founded in 2013, Spero Therapeutics maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$1.07
Last synced: 2026-11-09
Market Cap
$62.31M
Change (1 day)
3.88%
Change (1 year)
-59.16%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Spero Therapeutics, Inc. (SPRO)
Category
Healthcare
Operating Margin for Spero Therapeutics, Inc. (SPRO)
Operating Margin as of November 2026 TTM: 14.02%
According to Spero Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 14.02%. At the end of 2025 the company had an operating margin of -0.04%.
Operating Margin history for Spero Therapeutics, Inc. from 2015 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 14.02% | -35,150.00% |
| 2025 | -0.04% | -99.97% |
| 2024 | -152.91% | -838.70% |
| 2023 | 20.70% | -123.83% |
| 2022 | -86.86% | -96.97% |
| 2021 | -2,865.50% | 237.94% |
| 2020 | -847.94% | 143.41% |
| 2019 | -348.36% | -67.72% |
| 2018 | -1,079.32% | -48.81% |
| 2017 | -2,108.64% | -78.74% |
| 2016 | -9,916.72% | 0.00% |
| 2015 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -97.25% |
US
|
|
| -149.01% | -110.63% |
US
|
|
| 25.57% | -98.18% |
AU
|
|
| 31.23% | -97.77% |
BE
|
|
| 29.35% | -97.91% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Spero Therapeutics, Inc.'s operating margin
What is Spero Therapeutics, Inc.'s operating margin?
Spero Therapeutics, Inc.'s operating margin is 14.02%, as of Nov 2026.
What was Spero Therapeutics, Inc.'s operating margin in 2025?
In 2025, Spero Therapeutics, Inc.'s operating margin was -0.04%, compared with -152.91% in 2024.
How has Spero Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Spero Therapeutics, Inc.'s operating margin was highest in 2023 (20.70%) and lowest in 2021 (-2,865.50%).
How does Spero Therapeutics, Inc.'s operating margin compare with similar companies?
Spero Therapeutics, Inc.'s operating margin (14.02%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.